Previous 10 | Next 10 |
2023-12-06 13:46:53 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) added ~41% on Wednesday after the Massachusetts area biotech disclosed early data from a Phase 2 trial evaluating its oral leukemia drug, tamibarotene, as a combination therapy. Based on data from 19 pat...
2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...
2023-12-06 12:33:41 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), Kamada Ltd (NASDAQ: KMDA), Syros Pha...
2023-12-06 09:57:12 ET DENVER, Colo., Dec. 6, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Sera Prognostics Inc (NASDAQ: SERA), MicroAlgo Inc (NASDAQ: MLGO), ZyVersa Therapeutics Inc (NASDAQ: ZVSA), Ka...
-- 100% CR/CRi Rate in Patients Treated with Tamibarotene, Venetoclax and Azacitidine Compared to 70% in Patients Randomized to Treatment with Venetoclax and Azacitidine Alone -- -- Triplet Regimen Continues to Demonstrate Favorable Tolerability -- -- Additional Data Expecte...
2023-11-14 13:53:09 ET Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Conference Call November 14, 2023 08:30 ET Company Participants Karen Hunady - Director of Investor Relations & Corporate Communications Nancy Simonian - President & Chief Executive Of...
2023-11-14 07:32:07 ET More on Syros Pharmaceuticals Syros Pharmaceuticals Q3 2023 Earnings Preview Syros Pharmaceuticals announces job cuts, CEO change Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceut...
– On track to report initial data from approximately 20 patients in SELECT-AML-1 trial in early December 2023 – – Expect to report pivotal CR data from SELECT-MDS-1 by mid-4Q 2024 – – Founding CEO, Nancy Simonian, M.D. to retire a...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Syros Pharmaceuticals Inc. (SYRS) is expected to report $-1.12 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Syros Pharmaceuticals Inc. Company Name:
SYRS Stock Symbol:
NASDAQ Market:
Syros Pharmaceuticals Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
2024-07-17 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...